Crown Bioscience opens oncology biomarker R&D centre in California

By Murielle Gonzalez | Published: 13-May-2019

New custom-designed 32,000 sqft facility in San Diego to support the growth of both oncology biomarker and inflammation service portfolios

Crown Bioscience has announced the opening of a new facility in San Diego, California. The new site will become CrownBio’s International Centre of Excellence for oncology biomarker and inflammation services.

CrownBio’s presence in San Diego has grown from 17 employees in 2015 to more than 70 to date, with additional hiring expected.

The new building is a custom-designed 32,000 sqft facility that provides the additional capacity required to support the growth of CrownBio forecasts in its oncology biomarker and inflammation service portfolios.

CrownBio said that as part of the expansion, significant investment was made in the latest flow cytometry, radiation and imaging technologies.

Last December, CrownBio announced the expansion of its existing translational oncology research capacity at its site in Suzhou, Jiangsu, China.

Expanding portfolio

In the newly created Centre of Excellence, CrownBio will enhance its current translational platforms by expanding its existing service portfolio, as well as develop an additional new suite of oncology and inflammation platforms.

The fully-operational facility is designed to ensure a streamlined workflow to optimise study efficiency.

Featuring a state-of-the-art ABSL-2 vivarium and laboratory housing an infectious suite and quarantine facilities, the new site hosts laboratory space dedicated to storing cryo-preserved cells and tissue, including the world’s largest commercially available collection of patient-derived xenograft (PDX) models, the company claims.

“The establishment of our International Centre of Excellence in San Diego is both an indicator of our continued growth and a commitment to our global and domestic customers,” said CrownBio COO, Yangzhou Wang. “The expansion allows us to add to our talented and diverse workforce, which will, in turn, support the development of novel cancer therapies globally.”

You may also like